A Clinical Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder

University of Calgary1 site in 1 country80 target enrollmentMarch 4, 2021

ConditionsDepression Treatment Resistant Depression

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Depression
Sponsor: University of Calgary
Enrollment: 80
Locations: 1
Primary Endpoint: Change in the MADRS total score
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary goals of this proof of concept clinical trial are to determine the effectiveness, safety and tolerability of oral FMT in adults with Treatment Resistant Depression (TRD).

Detailed Description

This study is a phase 2/3, double-blinded, randomized controlled trial (RCT) in which 80 adults with TRD being treated with an approved antidepressant medication will be assigned to either FMT capsules or identically appearing placebo capsules. Participant will be followed for f for 14 weeks post FMT. This extended observation period will allow us to see, whether FMT leads to sustainable improvements in depression and changes in intestinal microbiome

Registry

clinicaltrials.gov

Start Date

March 4, 2021

End Date

December 4, 2024

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University of Calgary

Responsible Party

Principal Investigator

Valerie Taylor

Head of Psychiatry

University of Calgary

Eligibility Criteria

Inclusion Criteria

•Between 18-65 years of age:
•Participants should be at least 18 years old and not older than 65 years at the day of screening
•Have a primary diagnosis of MDD according to the M.I.N.I. International Neuropsychiatric Interview (MINI)47
•Medical history suggestive of Treatment Resistant Depression (TRD). (inadequate response to at least 2 approved antidepressants. at least one of which is in the current episode of depression)48
•Have been on a current treatment with a approved antidepressant at an adequate dose for at least 8 weeks
•A MADRS score of ≥ 19 at screening and visit 2
•Additional Inclusion Criteria:
•Participants who will be included in the IBS-D cohort should have a confirmed diagnosis of IBS-D as indicated by the referring gastroenterologist.

Exclusion Criteria

•Participant meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5)1 Criteria for the following conditions according to the M.I.N.I: f) Substance Use Disorder within the last 3 months. \*(Criteria should include Alcohol and non-alcohol substances except Cannabis) g) Moderate or severe Substance use disorder for Cannabis use the last 3 months h) Active Anorexia Nervosa or Bulimia nervosa i) Schizophrenia or schizoaffective disorder j) Active suicidality
•Regular intake of non-steroidal anti-inflammatory drugs, antibiotics, or iron supplements for medical purposes in the 3 months prior to study entry
•Use of prebiotics or probiotics for medical purposes for more than 2 weeks within the last 3 months
•Clinically diagnosed chronic gastrointestinal diseases (IBD, Crohn's disease, Ulcerative colitis, Celiac disease)
•Conditions causing immune suppression
•Not breastfeeding, pregnant or seeking to get pregnant during the course of this study. Be using an acceptable method of birth control (implants, injectable, combined oral contraceptives, IUDs, sexual abstinence or a vasectomized partner)
•Reported allergy to Vancomycin or Nitazoxanide

Outcomes

Primary Outcomes

Change in the MADRS total score

Time Frame: from baseline (pre-intervention) to the final visit (week 13)

To evaluate the effectiveness of adjunct oral FMT as compared to placebo with currently accepted approved therapy for depression

Secondary Outcomes

GI tolerability of patients with Irritable Bowel Syndrome (IBS)(from baseline (pre-intervention) to the final visit (week 13))
Side effects as reported on the Toronto Side Effect Scale (TSES)(from baseline (pre-intervention) to the final visit (week 13))